The invention concerns a synthesis process of a compound of the following formula (I) or one of the salts thereof,

##STR00001## wherein R represents a COOH, CH.sub.2OH or CHO group, comprising the step according to which the but-3-ene-1,2-diol (BDO) is subjected to an oxidation in the presence of a catalyst, said catalyst comprising an active phase based on at least one noble metal selected from palladium, gold, silver, platinum, rhodium, osmium, ruthenium and iridium, and a support containing alkaline sites.

The invention also concerns the application of this reaction to the preparation of bioavailable compounds of methionine used, in particular, in animal nutrition.

The invention concerns a synthesis process of a compound of the following formula (I) or one of the salts thereof,

##STR00001## wherein R represents a COOH, CH.sub.2OH or CHO group, comprising the step according to which the but-3-ene-1,2-diol (BDO) is subjected to an oxidation in the presence of a catalyst, said catalyst comprising an active phase based on at least one noble metal selected from palladium, gold, silver, platinum, rhodium, osmium, ruthenium and iridium, and a support containing alkaline sites.

The invention also concerns the application of this reaction to the preparation of bioavailable compounds of methionine used, in particular, in animal nutrition.

The invention concerns a synthesis process of a compound of the following formula (I) or one of the salts thereof,

##STR00001## wherein R represents a COOH, CH.sub.2OH or CHO group, comprising the step according to which the but-3-ene-1,2-diol (BDO) is subjected to an oxidation in the presence of a catalyst, said catalyst comprising an active phase based on at least one noble metal selected from palladium, gold, silver, platinum, rhodium, osmium, ruthenium and iridium, and a support containing alkaline sites.

The invention also concerns the application of this reaction to the preparation of bioavailable compounds of methionine used, in particular, in animal nutrition.

This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: ##STR00001##
wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: ##STR00002##
R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen or lower alkyl, R.sup.4 is lower alkyl, hydroxyl, carboxyl, or amine, R.sup.5 is hydrogen, lower alkyl, or halide, R.sup.6 is hydroxyl or substituted thiol, and each R.sup.7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.

This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to:

##STR00001##

wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from:

##STR00002##

R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen or lower alkyl, R.sup.4 is lower alkyl, hydroxyl, carboxyl, or amine, R.sup.5 is hydrogen, lower alkyl, or halide, R.sup.6 is hydroxyl or substituted thiol, and each R.sup.7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.

A moisture-curable polyolefin formulation comprising a (hydrolyzable silyl group)-functional polyolefin prepolymer and a condensation-cure catalyst system comprising and/or made from mixture of a compound that is a carboxamidine or a guanidine and a compound that is a cobalt acetylacetonate or a zinc acetylacetonate, wherein each compound independently is unsubstituted or substituted. Also, methods of making and using same, a cured polyolefin made therefrom, and articles containing or made from same. Also, condensation-cure catalyst systems useful therein.

A moisture-curable polyolefin formulation comprising a (hydrolyzable silyl group)-functional polyolefin prepolymer and a condensation-cure catalyst system comprising and/or made from mixture of a compound that is a carboxamidine or a guanidine and a compound that is a cobalt acetylacetonate or a zinc acetylacetonate, wherein each compound independently is unsubstituted or substituted. Also, methods of making and using same, a cured polyolefin made therefrom, and articles containing or made from same. Also, condensation-cure catalyst systems useful therein.

Disclosed is a stabilized acyclic saccharide composite, which includes a LDH-based (layered double hydroxide-based) material and acyclic saccharides intercalated in interlayer regions of the LDH-based material. The acyclic saccharides stabilized and trapped in the LDH-based material give an opportunity for direct functionalization to other valuable molecules in the pharmaceutical, chemical or carbohydrate industries. Further, a novel pathway for saccharide transformation and aldol condensation without the drawbacks associated with enzymatic catalysts is achieved through the acyclic saccharides trapped by the LDH-based material.

Disclosed is a stabilized acyclic saccharide composite, which includes a LDH-based (layered double hydroxide-based) material and acyclic saccharides intercalated in interlayer regions of the LDH-based material. The acyclic saccharides stabilized and trapped in the LDH-based material give an opportunity for direct functionalization to other valuable molecules in the pharmaceutical, chemical or carbohydrate industries. Further, a novel pathway for saccharide transformation and aldol condensation without the drawbacks associated with enzymatic catalysts is achieved through the acyclic saccharides trapped by the LDH-based material.

This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to:

##STR00001##

wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from:

##STR00002##

R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen or lower alkyl, R.sup.4 is lower alkyl, hydroxyl, carboxyl, or amine, R.sup.5 is hydrogen, lower alkyl, or halide, R.sup.6 is hydroxyl or substituted thiol, and each R.sup.7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.